- Home
- KLXE vs BCAB Comparison
KLXE vs BCAB Comparison
Compare KLXE & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KLXE | BCAB |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8M | 12.5M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KLXE | BCAB |
|---|---|---|
| Price | $2.68 | $0.17 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 265.9K | ★ 1.6M |
| Earning Date | 06-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.19 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $636,600,000.00 | $300,000.00 |
| Revenue This Year | $3.31 | N/A |
| Revenue Next Year | $4.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.46 | $0.13 |
| 52 Week High | $4.36 | $1.43 |
Technical Indicators
Market Signals| Indicator | KLXE | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 38.09 |
| Support Level | $1.61 | $0.14 |
| Resistance Level | $3.06 | $0.27 |
| Average True Range (ATR) | 0.32 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 48.95 | 11.00 |
Price Performance
Historical ComparisonAbout KLXE KLX Energy Services Holdings Inc.
KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.